Immunic Inc Dossier
Qualitative Analysis
Business overview
Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases. Headquartered in New York City and founded in 2016, the company focuses on selective oral drugs in immunology. Its lead development program is vidofludimus calcium (IMU-838), an orally administered investigational small molecule designed to combine direct neuroprotective effects through Nurr1 activation with anti-inflammatory activity via selective DHODH inhibition. The company's pipeline also includes earlier-stage programs such as IMU-856 and IMU-381, aimed at building a broader therapeutics platform addressing neurodegenerative, chronic inflammatory, and autoimmune-related diseases.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing lead asset vidofludimus calcium (IMU-838) through Phase 3 clinical trials (ENSURE-1 and ENSURE-2) for relapsing multiple sclerosis (RMS) and preparing for a planned Phase 3 program in primary progressive multiple sclerosis (PPMS).
Expected impact: Establish vidofludimus calcium as a differentiated oral therapy combining immune modulation (DHODH inhibition) with direct neuroprotection (Nurr1 activation).
Transitioning Immunic from a clinical-stage development company into a commercial-stage neurology organization, highlighted by the appointment of Erik Lundgren (former Genentech/Roche executive with deep MS launch experience) as CEO.
Expected impact: Ensure commercial strategy, launch execution, and regulatory navigation are led by experienced industry veterans.
Exploring strategic alternatives, including potential licensing, partnering, or financing options, to advance the Phase 2-ready IMU-856 program (SIRT6 modulator for gastrointestinal diseases and weight management).
Expected impact: Maximize the value of the gastrointestinal pipeline while preserving internal capital for the lead MS program.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Secured up to $400 million in gross proceeds (with $200 million received upfront in February 2026) to fund operations into late 2027, covering key Phase 3 readouts and NDA preparation.
Terms: $200 million upfront received upon closing on February 17, 2026, with potential for up to an additional $200 million.